^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AZD5863

    i
    Company:
    AstraZeneca, Harbour BioMed
    Drug class:
    CD3 agonist, CLDN18.2 inhibitor
    Related drugs:
    Apply
    Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors (D9750C00001) (NCT06005493)
    Phase 1/2
    AstraZeneca
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    07/11/2023
    Primary completion :
    12/16/2026
    Completion :
    12/16/2026
    CLDN18
    |
    CLDN18.2 positive • CLDN1 positive
    |
    AZD5863